Efficacy News and Research

RSS

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders, convened more than 1700 researchers, delegates, autism specialists and students from 40 countries for the 13th Annual International Meeting for Autism Research (IMFAR), the world's largest scientific gathering on autism research, from May 15 through May 17 at the Atlanta Marriott Marquis in Atlanta, GA.

15 May 2014

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.

15 May 2014

Study: Wider use of medications may help reduce substance abuse, related hospital admissions

A comparatively new form of a medication for alcohol and opioid dependence that's injected once a month instead of taken orally once a day appears to be significantly more effective than some other medications - because more patients actually continue the prescribed regimen.

15 May 2014

New technology has potential to make production of biotech medicines simpler

The final step in the production of a biotech medicine is finishing with the correct sugar structure. This step is essential for the efficacy of the medicine, but it also makes the production process very complex and expensive.

15 May 2014

‘Lessebo’ effect implications for Parkinson’s therapies

Patients with Parkinson’s disease have a reduced objective response to treatment given in a clinical trial if they know they may be taking a placebo, research shows.

14 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

A study which will be published in the May 2014 issue of Experimental Biology and Medicine was aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone.

14 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Patient-centered care associated with improved patient outcomes

Providing patient-centered care consistently in clinical practice requires practitioners who are able to recognize that different clinical situations require different approaches and are skilled enough to adapt.

14 May 2014

Scientists discover novel protein fragments that may protect against Alzheimer's disease

The devastating loss of memory and consciousness in Alzheimer's disease is caused by plaque accumulations and tangles in neurons, which kill brain cells.

14 May 2014

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.

13 May 2014

Da Volterra presents promising results of DAV-132 compound for prevention of severe C. diff infections

Da Volterra, a leading biopharmaceutical company in the field of bacterial resistance, announces today very promising new results about DAV132 in the prevention of the side effects of antibiotics and the occurrence of severe Clostridium difficile infections.

13 May 2014

Researchers use natural molecule to treat type 2 diabetes

Researchers at the Universit- Laval Faculty of Medicine, the Quebec Heart and Lung Institute Research Center, and the Institute of Nutrition and Functional Foods have discovered a natural molecule that could be used to treat insulin resistance and type 2 diabetes.

13 May 2014

Leadless pacemaker technology shows promising performance after 12 months

Vivek Reddy, MD, Director of Arrhythmia Services for The Mount Sinai Hospital, reported his promising12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Dr. Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco, CA.

12 May 2014

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

12 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging aims at the visualization of molecules or molecular events that occur at the cellular level. Clearly it also allows the possibility of looking inside the biochemical pathway at the cellular level and therefore enables us to look at the onset of diseases well before they are resolved into structural change.

From Bruker BioSpin Group 12 May 2014

Grape skin extract: A new possibility in diabetes treatment

The diabetes rate in the United States nearly doubled in the past 10 years. Approximately 26 million Americans are now classified as diabetic, stressing an urgent need for safe and effective complementary strategies to enhance the existing conventional treatment for diabetes.

12 May 2014

Efficacy News and Research

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Study: Wider use of medications may help reduce substance abuse, related hospital admissions

New technology has potential to make production of biotech medicines simpler

‘Lessebo’ effect implications for Parkinson’s therapies

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Patient-centered care associated with improved patient outcomes

Scientists discover novel protein fragments that may protect against Alzheimer's disease

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Da Volterra presents promising results of DAV-132 compound for prevention of severe C. diff infections

Researchers use natural molecule to treat type 2 diabetes

Leadless pacemaker technology shows promising performance after 12 months

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Grape skin extract: A new possibility in diabetes treatment

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News